Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab + pomalidomide + zanubrutinib as first-line therapy in follicular lymphoma
ChiCTR2500106075Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of obinutuzumab, pomalidomide and zanubrutinib in follicular lymphoma (FL), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete remission rate after 6 cycles of therapy. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
obinutuzumabpomalidomidezanubrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ChiCTR2500106075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106075.